Sugi Predict

Sugi Predict / Compounds / SCHEMBL715494

SCHEMBL715494

SCHEMBL715494

CCOC(=O)CC[C@H](NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 2/20 0.58
▸ ACHE P22303 2/20 0.58
▸ CACNA1F O60840 1/20 0.58
▸ CACNA1D Q01668 1/20 0.58
▸ CACNA1S Q13698 1/20 0.58
▸ CACNA1C Q13936 1/20 0.58
▸ SIRT2 Q8IXJ6 2/20 0.56
▸ SIRT1 Q96EB6 2/20 0.56
▸ FOLH1 Q04609 2/20 0.54
▸ CASP1 P29466 2/20 0.53
▸ CTSL P07711 2/20 0.52
▸ PPARG P37231 1/20 0.52
▸ PPARA Q07869 1/20 0.52
▸ CTSS P25774 1/20 0.52
▸ CTSK P43235 3/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29127287 1.00 BCHE (0.58) BCHEACHECACNA1FCACNA1DCACNA1S
SCHEMBL28704605 0.92 BCHE (0.58) BCHEACHECACNA1FCACNA1DCACNA1S
SCHEMBL6849362 0.92 FOLH1 (0.58) SIRT2SIRT1FOLH1CASP1PPARG
SCHEMBL11893028 0.92 FOLH1 (0.58) SIRT2SIRT1FOLH1CASP1PPARG
SCHEMBL7373019 0.92 FOLH1 (0.58) SIRT2SIRT1FOLH1CASP1PPARG
SCHEMBL8723888 0.90 SIRT2 (0.58) BCHEACHECACNA1FCACNA1DCACNA1S
SCHEMBL6299667 0.90 FOLH1 (0.56) SIRT2SIRT1FOLH1CASP1CTSL
SCHEMBL5970693 0.90 FOLH1 (0.56) SIRT2SIRT1FOLH1CASP1CTSL
SCHEMBL220498 0.90 FOLH1 (0.56) SIRT2SIRT1FOLH1CASP1CTSL
SCHEMBL7262083 0.88 BCHE (0.59) BCHEACHECACNA1FCACNA1DCACNA1S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117143022-B Synthesis method of glutaminyl ethyl imidazole 上海克琴科技有限公司 2024-07-26 — — CN claimed
CN-117143022-A Synthesis method of glutaminyl ethyl imidazole 上海克琴科技有限公司 2023-12-01 — — CN claimed
US-20250289848-A1 PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2025-09-18 — — US disclosed
US-12269899-B2 Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2025-04-08 — — US disclosed
CN-117143022-B Synthesis method of glutaminyl ethyl imidazole 上海克琴科技有限公司 2024-07-26 — — CN disclosed
CN-117143022-B Synthesis method of glutaminyl ethyl imidazole 上海克琴科技有限公司 2024-07-26 — — CN disclosed
CN-117143022-A Synthesis method of glutaminyl ethyl imidazole 上海克琴科技有限公司 2023-12-01 — — CN disclosed
CN-117143022-A Synthesis method of glutaminyl ethyl imidazole 上海克琴科技有限公司 2023-12-01 — — CN disclosed
US-20220024977-A1 PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2022-01-27 — — US disclosed
US-20120053159-A1 ISOTOPOLOGUES OF LENALIDOMIDE CELGENE CORPORATION 2012-03-01 — — US disclosed
EP-2396312-A1 ISOTOPOLOGUES OF LENALIDOMIDE CELGENE CORPORATION (US) 2011-12-21 — — EP disclosed
WO-2010093434-A1 ISOTOPOLOGUES OF LENALIDOMIDE CELGENE CORPORATION (US) 2010-08-19 — — WO disclosed
US-20090093414-A1 Hyaluronic Acid-Methotrexate Conjugate DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2009-04-09 — — US disclosed
EP-1739097-A1 HYALURONIC ACID/METHOTREXATE COMPOUND DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2007-01-03 — — EP disclosed
EP-0728018-B1 New enzymes and prodrugs for ADEPT WELLCOME FOUND (GB) 2003-08-06 — — EP disclosed
US-6319702-B1 NUCLEOTIDE SEQUENCS CODING AN ENZYMATIC POLYPEPTIDE AND CELL TARGETING COMPOUND; FOR USE IN TREATMENT OF CANCER GLAXO WELLCOME, INC. 2001-11-20 — — US disclosed
US-6140100-A CONJUGATE POLYPEPTIDE WHICH IS TISSUE PREFERENTIAL; ANTICARCINOGENIC AGENTS GLAXO WELLCOME INC. (US) 2000-10-31 — — US disclosed
EP-0728018-A1 THERAPY THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-28 — — EP disclosed
WO-1995013095-A2 THERAPY THE WELLCOME FOUNDATION LIMITED (GB) 1995-05-18 — — WO disclosed
US-5326908-A Process for the preparation of asparagine NSC TECHNOLOGIES LLC 1994-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053159-A1 ISOTOPOLOGUES OF LENALIDOMIDE CDK4, SRMS, DAP3 BCHE 4870/4885ACHE 4853/4885CACNA1F 3985/4885
US-20250289848-A1 PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION CTNNB1, CTNNBL1, CTNND1 BCHE 286/4885ACHE 2858/4885CACNA1F 4320/4885
US-12269899-B2 Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction CTNNB1, CTNNBL1, CTNND1 BCHE 768/4885ACHE 2416/4885CACNA1F 4371/4885
US-20090093414-A1 Hyaluronic Acid-Methotrexate Conjugate CD44, MTX1, MTX2 BCHE 395/4885ACHE 1868/4885CACNA1F 4839/4885
US-20220024977-A1 PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION CTNNB1, CTNNBL1, CTNND1 BCHE 286/4885ACHE 2858/4885CACNA1F 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.